BUZZ-Tempest Therapeutics rises on partner‑funded plan for new cancer drugs

Reuters02-11

BUZZ-Tempest <a href="https://laohu8.com/S/LENZ">Therapeutics</a> rises on partner‑funded plan for new cancer drugs

** Shares of cancer drug developer Tempest Therapeutics TPST.O rise 2.07% to $2.47 premarket

** Co says it will focus on developing its newly acquired cancer programs, while keeping costs low through partner-funded trials

** Co's TPST-2003, a dual‑targeting CAR‑T for blood cancers, is already being tested in China; larger study expected end-2026 with early data in 2027 – co says

** Co says TPST-4003 aims to treat cancer without complex cell manufacturing, plans to move it into early studies with partner support

** Shares were down ~73% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2610937358?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-11 20:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610937358","market":"nz","top_or_hot":-1,"title":"BUZZ-Tempest Therapeutics rises on partner‑funded plan for new cancer drugs","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Tempest <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> rises on partner‑funded plan for new cancer drugs</title></head><body><p>** Shares of cancer drug developer Tempest Therapeutics <span>TPST.O</span> rise 2.07% to $2.47 premarket</p><p>** Co says it will focus on developing its newly acquired cancer programs, while keeping costs low through partner-funded trials</p><p>** Co's TPST-2003, a dual‑targeting CAR‑T for blood cancers, is already being tested in China; larger study expected end-2026 with early data in 2027 – co says</p><p>** Co says TPST-4003 aims to treat cancer without complex cell manufacturing, plans to move it into early studies with partner support</p><p>** Shares were down ~73% in 2025</p><p> (Reporting by Sahil Pandey in Bengaluru)</p><p> ((Sahil.Pandey@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Tempest Therapeutics rises on partner‑funded plan for new cancer drugs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Tempest Therapeutics rises on partner‑funded plan for new cancer drugs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-11 20:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Tempest <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> rises on partner‑funded plan for new cancer drugs</title></head><body><p>** Shares of cancer drug developer Tempest Therapeutics <span>TPST.O</span> rise 2.07% to $2.47 premarket</p><p>** Co says it will focus on developing its newly acquired cancer programs, while keeping costs low through partner-funded trials</p><p>** Co's TPST-2003, a dual‑targeting CAR‑T for blood cancers, is already being tested in China; larger study expected end-2026 with early data in 2027 – co says</p><p>** Co says TPST-4003 aims to treat cancer without complex cell manufacturing, plans to move it into early studies with partner support</p><p>** Shares were down ~73% in 2025</p><p> (Reporting by Sahil Pandey in Bengaluru)</p><p> ((Sahil.Pandey@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nL4N3Z710Y:1","article_id":"2610937358","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610937358","pubTimestamp":1770813594,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Tempest Therapeutics rises on partnerfunded plan for new cancer drugs** Shares of cancer drug developer Tempest Therapeutics TPST.O rise 2.07% to $2.47 premarket** Co says it will focus on developing its newly acquired cancer programs, while keeping costs low through partner-funded trials** Co's TPST-2003, a dualtargeting CART for blood cancers, is already being tested in China; larger study expected end-2026 with early data in 2027 – co says** Co says TPST-4003 aims to treat cancer without complex cell manufacturing, plans to move it into early studies with partner support** Shares were down ~73% in 2025  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","TPST":"Tempest Therapeutics Inc."},"translate_title":"BUZZ-Tempest Therapeutics因合作伙伴资助的新型癌症药物计划而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TPST":0.9},"content_text":"BUZZ-Tempest Therapeutics rises on partner‑funded plan for new cancer drugs** Shares of cancer drug developer Tempest Therapeutics TPST.O rise 2.07% to $2.47 premarket** Co says it will focus on developing its newly acquired cancer programs, while keeping costs low through partner-funded trials** Co's TPST-2003, a dual‑targeting CAR‑T for blood cancers, is already being tested in China; larger study expected end-2026 with early data in 2027 – co says** Co says TPST-4003 aims to treat cancer without complex cell manufacturing, plans to move it into early studies with partner support** Shares were down ~73% in 2025 (Reporting by Sahil Pandey in Bengaluru) ((Sahil.Pandey@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2610937358","isCrawlerRequest":true}